Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)

Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)

Medical Conditions

Cholangitis
Liver Cirrhosis, Biliary
Pruritus


This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


This is a 2-part study in PBC participants with cholestatic pruritus and will evaluate the efficacy, safety and impact on health-related quality of life of linerixibat compared with placebo.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Aug 2021 Oct 2024

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Participants will receive linerixibat.

Intervention Arm Group : Participants receiving linerixibat;Participants receiving linerixibat followed by placebo;Participants receiving placebo followed by linerixibat;

Intervention Type : DRUG
Intervention Description : Participants will receive placebo.

Intervention Arm Group : Participants receiving linerixibat followed by placebo;Participants receiving placebo;Participants receiving placebo followed by linerixibat;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • GSK Investigational Site
    Cambridge
    CB2 0QQ
  • GSK Investigational Site
    London
    NW3 2QG
  • GSK Investigational Site
    Southampton
    SO16 6YD
  • GSK Investigational Site
    Durham
    DH1 5TW
  • GSK Investigational Site
    Surrey
    RH1 5RH
  • GSK Investigational Site
    Liverpool
    L9 7AL
  • GSK Investigational Site
    Plymouth
    PL6 8DH
  • GSK Investigational Site
    Hull
    HU3 2JZ
  • GSK Investigational Site
    Reading Berkshire
    RG1 5AN
  • GSK Investigational Site
    Basingstoke
    RG24 9AA
  • GSK Investigational Site
    London
    E1 1FR
  • GSK Investigational Site
    Newcastle Upon Tyne
    NE4 6BE


The study is sponsored by GlaxoSmithKline




We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?

Read full details for Trial ID: NCT04950127
Last updated 24 February 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.